These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34860262)

  • 1. Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes.
    Qiu M; Wei W; Wei XB; Liu SY
    Eur J Clin Pharmacol; 2022 Apr; 78(4):695-697. PubMed ID: 34860262
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.
    Wei XB; Wei W; Ding LL; Liu SY
    Prim Care Diabetes; 2021 Apr; 15(2):208-211. PubMed ID: 32912710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.
    Tanner M
    Ann Intern Med; 2021 Jun; 174(6):JC67. PubMed ID: 34058114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
    Tanner M
    Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
    Chang R; Liu SY; Zhao LM
    Medicine (Baltimore); 2021 Nov; 100(47):e27802. PubMed ID: 34964748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 9. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.
    Aroda VR; Billings LK
    J Am Coll Cardiol; 2023 Aug; 82(6):526-528. PubMed ID: 37532423
    [No Abstract]   [Full Text] [Related]  

  • 12. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.
    Kelsey MD; Newby LK
    Ann Intern Med; 2022 Mar; 175(3):JC26. PubMed ID: 35226528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. For Patients with Type 2 Diabetes Mellitus Who Are Taking a GLP-1 Receptor Agonist, an SGLT2 Inhibitor May Be Preferred to a Sulfonylurea as Add-on Therapy.
    Ebell MH
    Am Fam Physician; 2021 Oct; 104(4):424. PubMed ID: 34652104
    [No Abstract]   [Full Text] [Related]  

  • 19. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.
    Marasinghe DH; Butalia S; Garies S; Drummond N; Kim JW; Senior PA
    Can J Diabetes; 2022 Jul; 46(5):487-494. PubMed ID: 35739042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.